Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: Incorporation into DNA is a necessary step

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4937-4943

  Rodriguez Jr , Carlos O ^a   Gandhi, Varsha ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APHIDICOLIN; GUANINE ARABINOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL SYNCHRONIZATION; CONTROLLED STUDY; DNA DEGRADATION; DNA SYNTHESIS; FLOW CYTOMETRY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; T LYMPHOBLAST;

ANTINEOPLASTIC AGENTS; APHIDICOLIN; APOPTOSIS; ARABINONUCLEOSIDES; CELL CYCLE; DNA FRAGMENTATION; DNA, NEOPLASM; G1 PHASE; HUMANS; KINETICS; LEUKEMIA, T-CELL, ACUTE; S PHASE; T-LYMPHOCYTES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0345363112     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Lambe, C. U., Averett, D. R., Paff, M. T., Reardon, J. E., Wilson, J. G., and Krenitsky, T. A. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res., 55: 3352-3356, 1995.
2. Gandhi, V., Plunkett, W., Rodriguez, C. O., Jr., Nowak, B. J., Du, M., Ayres, M., Kisor, D. F., Mitchell, B. S., Kurtzberg, J., and Keating, M. J. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J. Clin. Oncol., 16: 3607-3615, 1998.
3. Kurtzberg, J., Keating, M. J., Moore, J. O., Gandhi, V., Blaney, S., Gold, S., Ernst, T., Henslee-Downey, J., Chang, A., Kisor, D., Plunkett, W., and Mitchell, B. 2-amino-9-β-D-arabinosyl-6-methoxy-9H-guanine (GW 506: Compound 506U) is highly active in patients with T-cell malignancies: results of a Phase I trial in pediatric and adult patients with refractory hematological malignancies. Blood, 88: 669a, 1996.
4. Shewach, D. S., Daddona, P. E., Ashcraft, E., and Mitchell, B. S. Metabolism and selective cytotoxicity of 9-β-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res., 45: 1008-1014, 1985.
5. Rodriguez, C. O., Jr., Legha, J. K., Estey, E., Keating, M. J., and Gandhi, V. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin. Cancer Res., 3: 2107-2113, 1997.
6. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
7. Kufe, D. W., Major, P. P., Egan, E. M., and Beardsley, G. P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem., 255: 8997-900, 1980.
8. Huang, P., Chubb, S., and Plunkett, W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J. Biol. Chem., 265: 16617-16625, 1990.
9. Huang, P., and Plunkett, W. Fludarabine- and gemcitibine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother. Pharmacol., 36: 181-188, 1995.
10. Avery, T. L., Rehg, J. E., Lumm, W. C., Harwood, F. C., Santana, V. M., and Blakley, R. L. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res., 49: 4972-4978, 1989.
11. Cohen, A., Lee, J. W., and Gelfand, E. W. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood, 61: 660-666, 1983.
12. Carson, D. A., Kaye, J., and Seegmiller, J. E. Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J. Immunol., 121: 1726-1731, 1978.
13. Verhoef, V., and Fridland, A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts Cancer Res., 45: 3646-3650, 1985.
14. Shewach, D. S., and Mitchell, B. S. Differential metabolism of 9-β-D-arabinofuranosylguanine in human leukemic cells. Cancer Res., 49: 6498-6502, 1989.
15. Huang, P., and Plunkett, W. A quantitative assay for fragmented DNA in apoptotic cells. Anal. Biochem., 207: 163-167, 1992.
16. Oberhammer, F., Wilson, J. W., Dive, C., Morris, I. D., Hickman, J. A., Wakeling, A. E., Walker, P. R., and Sikorska, M. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J., 12: 3679-3684, 1993.
17. Collins, R. J., Harmon, B. V., Gobe, G. C., and Kerr, J. F. R. Internucleosomal DNA cleavage should not be the sole criterion for identifying apoptosis. Int. J. Radiat. Biol., 61: 451-453, 1992.
18. Falcieri, E., Martelli, A. M., Bareggi, R., Cataldi, A., and Cocco, L. The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in Molt-4 cells without concomitant DNA fragmentation. Biochem. Biophys. Res. Commun., 193: 19-25, 1993.
19. Huang, P., Robertson, L. E., Wright, S., and Plunkett, W. High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin. Cancer Res. 1: 1005-1013, 1995.
20. Huang, P., Ballal, K., and Plunkett, W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer Res., 57: 3407-3414, 1997.
21. Prus, K. L., Averett, D. R., and Zimmerman, T. P. Transport and metabolism of 9-β-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res., 50: 1817-1821, 1990.
22. Krenitsky, T. A., Tuttle, J. V., Koszalka, G. W., Chen, I. S., Beacham, L. M., Rideout, J. L., and Elion, G. B. Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J. Biol. Chem., 251: 4055-4061, 1976.
23. Wang, L., Karlsson, A., Arner, E. S., and Eriksson, S. Substrate specificity of mitochondrial 2′-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. J. Biol. Chem., 268: 22847-22852, 1993.
24. Gandhi, V., and Plunkett, W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res., 50: 3675-3680, 1990.
25. Shewach, D. S., Reynolds, K. K., and Hertel, L. Nucleotide specificity of human deoxycytidine kinase. Mol. Pharmacol., 42: 518-524, 1992.
26. Liliemark, J. O., and Plunkett, W. Regulation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in human leukemia cells by deoxycytidine 5′-triphosphate. Cancer Res., 46: 1079-1083, 1986.
27. Brockman, R. W., Cheng, Y. C., Schabel, F. M. J., and Montgomery, J. A. Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res., 40: 3610-3615, 1980.
28. Green, F. J., and Lewis, R. A. Partial purification and characterization of deoxyguanosine kinase from pig skin. Biochem J., 183: 547-553, 1979.
29. Lewis, R. A., and Link, L. Phosphorylation of arabinosyl guanine by a mitochondrial enzyme of bovine liver. Biochem. Pharmacol., 38: 2001-2006, 1989.
30. Sherley, J. L., and Kelly, T. J. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem., 263: 8350-8358, 1988.
31. Arner, E. S., Flygar, M., Bohman, C., Wallstrom, B., and Eriksson, S. Deoxycytidine kinase is constitutively expressed in human lymphocytes: consequences for compartmentation effects, unscheduled DNA synthesis, and viral replication in resting cells. Exp. Cell Res., 178: 335-342, 1988.
32. Gandhi, V., and Plunkett, W. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother. Pharmacol., 31: 11-17, 1992.
33. Spadari, S., Focher, F., Sala, F., Ciarrocchi, G., Koch, G., Falaschi, A., and Pedrali-Noy, G. Control of cell division by aphidicolin without adverse effects upon resting cells. Arzneimittelforschung, 35: 1108-1116, 1985.
34. Xu, Y. Z., and Plunkett, W. Regulation of thymidine kinase and thymidylate synthase in intact human lymphoblast CCRF-CEM cells. J. Biol. Chem., 268: 22363-22368, 1993.
35. Huang, P., and Plunkett, W. Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol. Pharmacol., 39: 449-455, 1991.
36. Parker, W. B., Shaddix, S. C., Chang, C. H., White, E. L., Rose, L. M., Brockman, R. W., Shortnacy, A. T., Montgomery, J. A., Secrist, J. A., and Bennett, L. L. J. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res., 51: 2386-2394, 1991.
37. Seymour, J. F., Huang, P., Plunkett, W., and Gandhi, V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin. Cancer Res., 2: 653-658, 1996.
38. Kucera, G. L., and Capizzi, R. L. 1-β-D-arabinofuranosylcytosine-diphosphatecholine is formed by the reversal of cholinephosphotransferase and not via cytidylyltransferase. Cancer Res., 52: 3886-3891, 1992.
39. Ono, K., Ohashi, A., Yamamoto, A., Matsukage, A., Takahasi, T., Saneyoshi, M., and Ueda, T. Inhibitory effects of 9-β-D-arabinofuranosylguanine 5′-triphosphate and 9-β-D-arabinofuranosyladenine 5′-triphosphate on DNA polymerases from murine cells and oncornavirus. Cancer Res., 39: 4673-4680, 1979.
40. Gandhi, V., Mineishi, S., Huang, P., Chapman, A. J., Yang, Y., Chen, F., Nowak, B., Chubb, S., Hertel, L. W., and Plunkett, W. Cytotoxicity, metabolism, and mechanisms of action of 2′,2′-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res., 55: 1517-1524, 1995.
41. Kufe, D., Spriggs, D., Egan, E. M., and Munroe, D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood, 64: 54-58, 1984.
42. Spriggs, D., Robbins, G., Ohno, Y., and Kufe, D. Detection of 1-β-D-arabinofuranosylcytosine incorporation into DNA in vivo. Cancer Res., 47: 6532-6536, 1987.
43. Rodriguez, C. O., Jr., and Gandhi, G. Differential cellular accumulation of arabinofuranosylguanine triphosphate and its incorporation into DNA in acute leukemia cell lines: relationship with cytotoxicity. Proc. Am. Assoc. Cancer Res., 40: 517, 1999.
44. O'Brien, S., Thomas, D., Kantarjian, H., Freireich, E., Koller, C., Cortes, G., Giles, F., Bivins, C., Lerner, S., Hodge, J., Spector, N., and Keating, M. Compound 506 has activity in mature lymphoid leukemia. Blood, 92: 490a, 1998.